Imatinib Al

Imatinib, the active ingredient in Imatinib Al, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It targets malignant cells that express the BCR‑ABL protein and is indicated for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing quality‑assured bulk and packaged product with full documentation for regulatory approval, ensuring timely delivery.

Imatinib acts on the BCR‑ABL tyrosine kinase pathway and is employed in specific oncologic indications.

- Chronic myeloid leukemia (CML): reduces proliferation of malignant leukemic cells and achieves disease control. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth driven by KIT/PDGFRA mutations. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission by targeting BCR‑ABL positive blasts.

Imatinib may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset often occurring early in therapy. - Edema: fluid accumulation, particularly in the extremities. - Muscle cramps or pain: transient musculoskeletal discomfort. - Fatigue: general tiredness that may affect daily activities.

Serious or Rare Side Effects: - Neutropenia or severe leukopenia: marked reduction in white blood cells increasing infection risk. - Hepatotoxicity: elevated liver enzymes or liver injury requiring monitoring. - Cardiac failure or left ventricular dysfunction: rare but potentially life‑threatening cardiac events.

When prescribing Imatinib, clinicians should observe several precautionary measures to ensure patient safety.

- Monitor blood counts: perform regular complete blood count tests to detect cytopenias. - Assess liver function: check hepatic enzymes before and during treatment for signs of toxicity. - Evaluate cardiac status: baseline and periodic echocardiograms are advised for patients with cardiac risk factors. - Review drug interactions: avoid concomitant use of strong CYP3A4 inhibitors or inducers without dose adjustment. - Counsel patients on pregnancy: discuss potential risks and advise effective contraception during therapy. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise Imatinib levels and risk adverse effects. - Potent CYP3A4 inducers (e.g., rifampicin, carbamazepine): can lower drug exposure and reduce efficacy. - Antacids containing aluminum or magnesium: may affect absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Warfarin or other anticoagulants: Imatinib may enhance anticoagulant effect, requiring INR monitoring. - QT‑prolonging agents (e.g., sotalol, quinidine): combined use may increase risk of cardiac arrhythmias.